Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Alternative disease management in Crohn's disease

Alternative strategies reduce the total cost of care for steroid treated chronically active Crohn's patients, reports October's American Journal of Gastroenterology.

News image

fiogf49gjkf04

Azathioprine is effective for the maintenance of a steroid free remission in Crohn's disease.

Thiopurine methyltransferase is important for the metabolism of azathioprine and influences the production of active azathioprine metabolites.

Dr Marla Dubinsky and colleagues assessed azathioprine dose selection based on pharmacogenetic testing of thiopurine methyltransferase and metabolite monitoring.

The research team evaluated whether this treatment may offer a safety and efficacy advantage over traditional dosing strategies.

The team performed a decision analysis to estimate the potential costs and effectiveness of thiopurine methyltransferase screening.

A decision analysis was also performed to estimate the potential costs and effectiveness of metabolite monitoring.

Costly strategy with thiopurine methyltransferase was $3861 vs $7142 with community care
American Journal of Gastroenterology

The team assessed whether the decision analysis can be used as disease management strategies for Crohn's disease.

Strategies applying thiopurine methyltransferase and/or metabolite monitoring to influence treatment decisions were compared to community care.

The researchers evaluated the impact on toxicity minimization and improved time to initial and sustained response.

A 1-year model was developed from the third-party payer perspective for mild to moderately chronically active, steroid-treated Crohn's disease patients.

Effectiveness and toxicity were defined by time to response and Crohn's activity index.

The team also defined effectiveness and toxicity as time to sustained response and reduction in leukopenic events, respectively.

The researchers conducted 1- and 2-way sensitivity analyses.

The team determined the effect of varying individual estimates from those used in the base-case analysis.

Metabolite monitoring, and thiopurine methyltransferase as compared to community care achieved an earlier time to initial response.

Thiopurine methyltransferase with metabolite monitoring strategies as compared to community care achieved an earlier time to initial response.

In addition the team found that sustained response as compared to community care achieved an earlier time to initial response.

The researchers noted that least costly strategy at 1 yr was thiopurine methyltransferase at $3861.

The research team found that the most costly strategy was community care at $7142.

Each alternative strategy was shown to dominate community care by less costs and faster time to response or sustained response.

The team reported that the cost-effectiveness rankings were robust to sensitivity analyses on key variables.

The addition of alternative strategies to community care may improve azathioprine outcomes.

The researchers also found that alternative strategies reduce the total cost of care for steroid treated chronically active Crohn's patients.

Dr Dubinsky's team concluded, “Thiopurine methyltransferase was more beneficial for initial response to treatment and metabolite monitoring being more beneficial for sustained response to treatment.”

Am J Gastroenterol 2005: 100(10): 2239
07 October 2005

Go to top of page Email this page Email this page to a colleague

 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us